Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021773 · ClinicalTrials.gov registry record · Phase 2
Assessment of LBR-101 In Chronic Migraine
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
NCT02021773 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 264 participants.
The verdict
NCT02021773, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
Interventions
- DRUG Placebo
- DRUG LBR-101 High Dose
- DRUG LBR-101 Low Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2014-01-31 |
| Est. Completion | 2015-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02021773
The ClinicalTrials.gov registry entry for NCT02021773 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02021773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02021773 about?
NCT02021773 is a clinical study titled "Assessment of LBR-101 In Chronic Migraine". The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
What is the current status of trial NCT02021773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2014-01-31. Estimated completion is 2015-03-31.
What interventions are being tested in trial NCT02021773?
The interventions under investigation include: Placebo (DRUG), LBR-101 High Dose (DRUG), LBR-101 Low Dose (DRUG).
Who is sponsoring clinical trial NCT02021773?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.